Lipocine Inc. Common Stock (LPCN)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn durable profits and can be bought at a discount to intrinsic value. Lipocine is a 14-employee clinical-stage biopharma using drug-delivery technology and developing TLANDO and other pipeline candidates. But the financials do not show a durable business. In fiscal year 2024, the year ended 2024-12-31, net income was $8,352 on $11.2M revenue. By fiscal year 2025, the year ended 2025-12-31, revenue fell to $2.0M and net income was $-9.6M, with diluted EPS of $-1.69. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $190,099 and net income was $-2.6M. That is a tiny revenue base and heavy losses. FairStock’s numbers at the 2026-10-13 close show a P/B of 0.61, which might hint at asset cheapness, but P/E is -0.88 and free cash flow yield is -83.8%, so the company is consuming cash at a rapid pace relative to its $13.4M market cap. Debt is low (D/E 0.01), which helps, but Piotroski 3/9 and Altman -8.09 point to weak financial strength and distress risk. The Lynch category is TURNAROUND—loss in the latest year after earlier profits. A turnaround needs commercial traction or pipeline success. I see no moat in tiny revenue, negative margins, and cash burn. The stock is near its 52-week low, but a low price alone is not a margin of safety when the business is losing money and may need capital. I would require evidence of stable positive cash flow before calling this a value opportunity.

In plain English: Lipocine is a small healthcare company that develops oral medicines and is still testing some products. It brings in very little money, loses money, and uses cash to fund its work. The stock price may look low compared with its accounting assets, but the weak business results make it hard to call cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer